17:58 , Jul 20, 2018 |  BC Week In Review  |  Company News

Kite looks to Gadeta for gamma delta T cell tech

Kite Pharma Inc. and Gadeta B.V. (Utrecht, the Netherlands) partnered to develop T cell therapies that express gamma delta TCRs for hematologic malignancies and solid tumors using Gadeta's platform. Kite, a subsidiary of Gilead Sciences...
20:06 , Jul 19, 2018 |  BC Extra  |  Company News

Kite, Gadeta in gamma delta T cell deal

Kite Pharma Inc. and Gadeta B.V. (Utrecht, the Netherlands) partnered to develop T cell therapies that express gamma delta TCRs for hematologic malignancies and solid tumors using Gadeta's platform. Kite, a subsidiary of Gilead Sciences...
07:00 , Aug 28, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Butyrophilin subfamily 3 member A1 (BTN3A1) Cell culture studies suggest a pivaloyloxymethyl-protected phosphoantigen prodrug could help treat cancer. In vitro, the phosphoantigen prodrug induced...